UY35381A - Pirrolotriazinas como inhibidores del canal del ion potasio - Google Patents

Pirrolotriazinas como inhibidores del canal del ion potasio

Info

Publication number
UY35381A
UY35381A UY0001035381A UY35381A UY35381A UY 35381 A UY35381 A UY 35381A UY 0001035381 A UY0001035381 A UY 0001035381A UY 35381 A UY35381 A UY 35381A UY 35381 A UY35381 A UY 35381A
Authority
UY
Uruguay
Prior art keywords
inhibitors
pirrolotriazinas
ion channel
potassium ion
function
Prior art date
Application number
UY0001035381A
Other languages
English (en)
Spanish (es)
Inventor
Govindrajulu Kavitha
Naveen Kumar Dhondi
Srinivasu Pothukanuri
Finlay Heather
Ashok Kumar Adisechan
Gunaga Prashantha
Lloyd John
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY35381A publication Critical patent/UY35381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001035381A 2013-03-11 2014-03-11 Pirrolotriazinas como inhibidores del canal del ion potasio UY35381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors

Publications (1)

Publication Number Publication Date
UY35381A true UY35381A (es) 2014-09-30

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035381A UY35381A (es) 2013-03-11 2014-03-11 Pirrolotriazinas como inhibidores del canal del ion potasio

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150228A1 (es) * 2012-06-11 2015-02-19 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida
ES2616025T3 (es) * 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolotriazinas como inhibidores de canales de iones potasio
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
EP2970295B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3344631A1 (en) * 2015-08-31 2018-07-11 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
IL261957B (en) 2016-03-28 2022-07-01 Incyte Corp Pyrrolotriazine compounds as TAM inhibitors
CN109415384B (zh) 2016-04-28 2022-01-11 武田药品工业株式会社 稠合杂环化合物
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
US10780068B2 (en) 2017-05-05 2020-09-22 Nino Sorgente Methods and compositions for improving eye health
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
KR20250007533A (ko) 2022-04-08 2025-01-14 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물
TW202506693A (zh) 2022-05-11 2025-02-16 美商福宏治療公司 化合物及其用途
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
HRP20030485A2 (en) * 2000-11-17 2004-08-31 Bristol Myers Squibb Co METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
PL378121A1 (pl) 2003-02-05 2006-03-06 Bristol-Myers Squibb Company Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
AR052771A1 (es) 2004-09-30 2007-04-04 Tibotec Pharm Ltd Pirimidinas biciclicas inhibidoras del vhc
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20080107408A (ko) 2006-03-07 2008-12-10 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
US20080064718A1 (en) 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
PT2041138E (pt) 2006-07-07 2014-10-07 Bristol Myers Squibb Co Inibidores de pirrolotriazina quinase
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101687874B (zh) 2007-04-18 2013-01-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
MX2010001824A (es) * 2007-08-17 2010-04-21 Icagen Inc Heterociclos como moduladores de canal de potasio.
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
CN102015719A (zh) 2008-03-06 2011-04-13 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US20110269740A1 (en) 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
CA2772642C (en) 2009-09-03 2017-08-29 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
PE20150228A1 (es) * 2012-06-11 2015-02-19 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Also Published As

Publication number Publication date
TW201444847A (zh) 2014-12-01
WO2014143610A1 (en) 2014-09-18
AR095208A1 (es) 2015-09-30
JP6427551B2 (ja) 2018-11-21
CN105008367A (zh) 2015-10-28
EP2970296B1 (en) 2016-12-21
JP2016512505A (ja) 2016-04-28
US9050345B2 (en) 2015-06-09
CN105008367B (zh) 2017-08-29
EP2970296A1 (en) 2016-01-20
US20140256719A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CU24414B1 (es) Lactamas n-(heteroarilo sustituido) fusionadas útiles en el tratamiento del crecimiento celular anormal
UY34648A (es) Amidas como inhibidores de pim
NI201500112A (es) Compuestos de azabencimidazol como inhibidores de isozimas pde4 para el tratamiento del snc y otros trastornos.
UY35630A (es) Carboxamidas primarias como inhibidores de btk
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
CR20120448A (es) Compuesto heterocíclico
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CL2018002583A1 (es) Derivado de morfolina
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.